Back to Awarded Treatment Trials
Awarded Trial: 02T-192
Grant ID
02T-192
Illness
Bipolar Depression
Primary Drug/Intervention
Aripiprazole
Primary Dosage
15mg-30mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
McElroy
Sample Size
30
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
MADRS, YMRS, CGI-BP, GAF-C, PANSS positive
Results
In patients with bipolar depression that did not respond to standard mood stabilizer treatment, aripiprazole was associated with a significant improvement in depression scores. However, only 45% of patients completed the 8-week trial. Forty-two percent of patients were responders (>50% reduction is MADRS scores) and 35% of patients achieved remission (MADRS <12). Akathisia was a common side effect.
Publication
McElroy S.L., Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck PE Jr. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord. 2007 Aug;101(1-3):275-81.
Link
http://www.ncbi.nlm.nih.gov/pubmed/17229469
PI Name
Susan McElroy
Degree
MD
Center
Psychiatric Professional Services, Inc.
Institution
University of Cincinnati College of Medicine
Address
231 Albert Sabin Way
City or Town
Cincinnati
State or Province
OH
Zip or Postal Code
45267
Country
USA
Email Address
Susan.McElroy@UC.edu